Effect of Sodium Zirconium Cyclosilicate on Hyperkalemia After Parathyroidectomy
Author Information
Author(s): Kang Jing, Li Sijia, Su Jinglin, Xiao Zhixue, Zhang Siyi, Liu Shuangxin, Ge Pingjiang
Primary Institution: Guangdong Provincial People’s Hospital, Southern Medical University, Guangzhou City, P.R. China
Hypothesis
Using sodium zirconium cyclosilicate (SZC) will lower the risk of hyperkalemia in patients with maintenance hemodialysis after parathyroidectomy.
Conclusion
SZC has the potential to reduce the occurrence of hyperkalemia and avoid urgent hemodialysis after parathyroidectomy.
Supporting Evidence
- Serum potassium in the experimental group was significantly lower than in the control group at 9 pm on the day of surgery.
- None in the experimental group required hemodialysis after surgery.
- Three patients in the control group required emergency hemodialysis or insulin and glucose treatment.
Takeaway
This study found that a medicine called SZC can help keep patients' potassium levels safe after surgery, so they don't need emergency treatments.
Methodology
Sixty-two patients were randomly divided into experimental and control groups, with the experimental group taking 10g of SZC before surgery.
Limitations
The study was single-blinded, and the control group did not receive a placebo.
Participant Demographics
{"experimental_group":{"number":31,"age":"47.9 ± 12.4","male_female_ratio":"16:15","dialysis_duration":"8.3 ± 3.6"},"control_group":{"number":31,"age":"51.5 ± 11.3","male_female_ratio":"14:17","dialysis_duration":"7.0 ± 2.7"}}
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, −0.6 to −0.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website